Developing Non-Traditional Antibiotics (AAC ed.)
Listen now
Description
Developing of non-traditional antibiotics promises novel strategies to combat multidrug-resistant organism but would they work? Are the feasible to develop? 

 Topics discussed: 
 • The notion of non-traditional antibiotics as potential therapeutics against MDR organisms 
 • Increasing our understanding on the clinical efficacy of non-traditional antibiotics 
 • Regulatory pathways for approval of such compounds
 Guest: Dr. John Rex, Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust.
 Visit https://aac.asm.org to browse issues and/or submit a manuscript.
More Episodes
The protozoan Lophomonas has been reported to be a pathogen of humans in a large number of case reports and case series. Most of these case reports describe infections of the respiratory tract. Editors in Conversation is joined by two experts to discuss this possible parasite. Some of the...
Published 02/23/24
Published 02/23/24
Tuberculosis is one of the most deadly infectious diseases that still causes significant burden of disease, particularly in the developing world.  The emergence of resistance to first line agents severely limits the therapeutic options and threaten the ability to control dissemination of this...
Published 02/09/24